Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Breast Cancer Res Treat. 2014 Feb;144(1):205-12. doi: 10.1007/s10549-014-2862-5. Epub 2014 Feb 8.
Over one million American women have a benign breast biopsy annually. Sclerosing adenosis (SA) is a common, but poorly understood benign breast lesion demonstrating increased numbers of distorted lobules accompanied by stromal fibrosis. Few studies of its association with breast cancer have been conducted, with contradictory results. We studied SA in the Mayo Benign Breast Disease (BBD) Cohort, which includes women who had benign biopsies at Mayo-Rochester 1967-2001. Breast cancer risk in defined subsets was assessed using standardized incidence ratios (SIRs), relative to the Iowa Surveillance, Epidemiology, and End Results registry. This BBD cohort of 13,434 women was followed for a median of 15.7 years. SA was present in 3,733 women (27.8 %) who demonstrated an SIR for breast cancer of 2.10 (95 % CI 1.91-2.30) versus an SIR of 1.52 (95 % CI 1.42-1.63) for the 9,701 women without SA. SA was present in 62.4 % of biopsies with proliferative disease without atypia and 55.1 % of biopsies with atypical hyperplasia. The presence of SA stratified risk in subsets of women defined by age, involution status, and family history. However, SA does not further stratify risk in women diagnosed with other forms of proliferative breast disease, either with or without atypia. SA is a common proliferative lesion of the breast which, as a single feature, conveys an approximate doubling of breast cancer risk. Its role in breast carcinogenesis remains undefined; its presence may aid in risk prediction for women after a breast biopsy.
每年有超过 100 万美国女性接受良性乳腺活检。硬化性腺病(SA)是一种常见但了解甚少的良性乳腺病变,表现为变形小叶数量增加,伴有间质纤维化。对其与乳腺癌的相关性进行了少量研究,但结果相互矛盾。我们研究了在梅奥良性乳腺疾病(BBD)队列中的 SA,该队列包括 1967 年至 2001 年在梅奥-罗切斯特接受良性活检的女性。使用标准化发病比(SIR)评估特定亚组的乳腺癌风险,与爱荷华州监测、流行病学和最终结果登记处相比。该 BBD 队列包括 13434 名女性,中位随访时间为 15.7 年。3733 名女性(27.8%)存在 SA,其乳腺癌 SIR 为 2.10(95%CI 1.91-2.30),而 9701 名无 SA 的女性的 SIR 为 1.52(95%CI 1.42-1.63)。SA 存在于无不典型增生的增生性疾病活检的 62.4%和有不典型增生的活检的 55.1%。SA 的存在使年龄、退化状态和家族史定义的女性亚组的风险分层。然而,SA 不能进一步分层诊断为其他形式的增生性乳腺疾病(无论是否存在不典型增生)的女性的风险。SA 是一种常见的乳腺增生性病变,作为单一特征,可使乳腺癌风险增加约一倍。其在乳腺癌发生中的作用尚不清楚;其存在可能有助于对乳腺活检后的女性进行风险预测。